GLIMEPIRIDE 1mg. IP + PIOGLITAZONE 15mg. IP + METFORMIN 500mg. IP

A triple-drug combination of anti-diabetic drugs that are used for glycemic control in patients with type 2 diabetes mellitus. Provides better control of blood sugar when single or dual therapy is not effective. Increases the amount of insulin released by the pancreas to lower blood glucose. (Maria L.A.D. Lestari, 2011) Improves insulin sensitivity, glycemic control, hypertension, dyslipidemia, and microalbuminuria in patients with diabetes mellitus. (Hung-Wei Liao, 2017) Significantly improves glycated hemoglobin and fasting plasma glucose levels and produces beneficial effects on serum lipids in patients with type 2 diabetes. (S Aronoff, 2000) A choice of drug for insulin-resistant type 2 diabetes mellitus patients having dyslipidemia, hypertension, or a history of cardiovascular disease. (Fahmida Alam, 2019) An effective agent in achieving glycemic control and ameliorating lipid profile in type 2 diabetes mellitus. (Giuseppe Derosa, 2009) A promising alternative in type 2 diabetic patients at high cardiovascular risk. (Giuseppe Derosa, 2009) An effective option that permits better compliance to therapy in patients with type 2 diabetes. (Giuseppe Derosa, 2009)